The study included 64 patients and was conducted in two segments.

Systemic sclerosis is a complex autoimmune condition marked by aberrant immune activation, widespread fibrosis and vasculopathy that affect the skin and multiple internal organs. The disease manifests ...

Diffuse cutaneous systemic sclerosis ("dcSSc") is a rare, progressive autoimmune disease characterized by immune activation, vasculopathy and fibrosis affecting the skin and internal organs, including ...

On March 5, 2026, Zura Bio announced that the design of its ongoing global Phase 2 TibuSURE trial of tibulizumab (ZB-106) in diffuse cutaneous systemic sclerosis was accepted for poster presentation ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Proximal weakness and elevated creatine kinase were ...

Please provide your email address to receive an email when new articles are posted on . Nearly 10% of patients with systemic sclerosis had systemic sclerosis sine scleroderma, a subtype without skin ...

A new study published in the journal of Autoimmunity Reviews that Hyaluronic acid (HA) fillers seem to be a safe, minimally invasive treatment for improving both functional and aesthetic ...

Systemic sclerosis (SSc), also referred to as scleroderma, is a rare autoimmune disease associated with vasculopathy, inflammation, and fibrosis of the skin and/or internal organs. Interstitial lung ...

Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced results from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine), a novel ...

Although less common than other subtypes of systemic sclerosis (SSc), systemic sclerosis sine scleroderma (ssSSc) makes up more than 8% of SSc cases and "should not be neglected," according to a new ...

A retrospective cohort study found that beta-blocker use is associated with a decreased risk for incident HF in certain SAID populations.